Theriva Biologics, Inc.
TOVX
$0.25
$0.000.77%
AMEX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 6.15% | 9.32% | -4.58% | -9.85% | -4.52% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -28.07% | -27.58% | -19.94% | -18.11% | -20.33% |
| Operating Income | 29.81% | 29.25% | 19.94% | 18.11% | 20.33% |
| Income Before Tax | 60.69% | 13.52% | 7.46% | 3.41% | -27.28% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 60.69% | 13.52% | 7.46% | 1.88% | -32.72% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 60.69% | 13.52% | 7.46% | 1.88% | -32.72% |
| EBIT | 29.81% | 29.25% | 19.94% | 18.11% | 20.33% |
| EBITDA | 29.95% | 29.35% | 19.93% | 18.04% | 20.31% |
| EPS Basic | 94.19% | 87.65% | 84.77% | 83.29% | 61.80% |
| Normalized Basic EPS | 91.93% | 91.32% | 85.82% | 83.85% | 74.54% |
| EPS Diluted | 94.19% | 87.65% | 84.77% | 83.29% | 61.80% |
| Normalized Diluted EPS | 91.93% | 91.32% | 85.82% | 83.85% | 74.54% |
| Average Basic Shares Outstanding | 835.30% | 1,059.29% | 799.76% | 571.08% | 376.34% |
| Average Diluted Shares Outstanding | 835.30% | 1,059.29% | 799.76% | 571.08% | 376.34% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |